Literature DB >> 22393059

Analysis of binding sites on complement factor I using artificial N-linked glycosylation.

Jose I Sanchez-Gallego1, Tom W L Groeneveld, Stefanie Krentz, Sara C Nilsson, Bruno O Villoutreix, Anna M Blom.   

Abstract

Factor I (FI) is a serine protease that inhibits all complement pathways by degrading activated complement components C3b and C4b. FI functions only in the presence of several cofactors, such as factor H, C4b-binding protein, complement receptor 1, and membrane cofactor protein. FI is composed of two chains linked by a disulfide bridge; the light chain comprises only the serine protease (SP) domain, whereas the heavy chain contains the FI membrane attack complex domain (FIMAC), CD5 domain, and low density lipoprotein receptor 1 (LDLr1) and LDLr2 domains. To better understand how FI inhibits complement, we used homology-based three-dimensional models of FI domains in an attempt to identify potential protein-protein interaction sites. Specific amino acids were then mutated to yield 20 recombinant mutants of FI carrying additional surface-exposed N-glycosylation sites that were expected to sterically hinder interactions. The Michaelis constant (K(m)) of all FI mutants toward a small substrate was not increased. We found that many mutations in the FIMAC and SP domains nearly abolished the ability of FI to degrade C4b and C3b in the fluid phase and on the surface, irrespective of the cofactor used. On the other hand, only a few alterations in the CD5 and LDLr1/2 domains impaired this activity. In conclusion, all analyzed cofactors form similar trimolecular complexes with FI and C3b/C4b, and the accessibility of FIMAC and SP domains is crucial for the function of FI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22393059      PMCID: PMC3340171          DOI: 10.1074/jbc.M111.326298

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Purification of C3b inactivator and demonstration of its two polypeptide chain structure.

Authors:  D T Fearon
Journal:  J Immunol       Date:  1977-10       Impact factor: 5.422

2.  Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.

Authors:  I Gigli; T Fujita; V Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

3.  CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b.

Authors:  Anna M Blom; Lena Kask; Björn Dahlbäck
Journal:  Mol Immunol       Date:  2003-01       Impact factor: 4.407

4.  Biosynthesis and postsynthetic processing of human C3b/C4b inactivator (factor I) in three hepatoma cell lines.

Authors:  G Goldberger; M A Arnaout; D Aden; R Kay; M Rits; H R Colten
Journal:  J Biol Chem       Date:  1984-05-25       Impact factor: 5.157

5.  Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome.

Authors:  V Fremeaux-Bacchi; M-A Dragon-Durey; J Blouin; C Vigneau; D Kuypers; B Boudailliez; C Loirat; E Rondeau; W H Fridman
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

6.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

7.  Human complement factor I does not require cofactors for cleavage of synthetic substrates.

Authors:  Stefanos A Tsiftsoglou; Robert B Sim
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

8.  Inhibition of platelet prothrombinase activity by a lupus anticoagulant.

Authors:  B Dahlbäck; I M Nilsson; B Frohm
Journal:  Blood       Date:  1983-07       Impact factor: 22.113

9.  Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1.

Authors:  M E Medof; V Nussenzweig
Journal:  J Exp Med       Date:  1984-06-01       Impact factor: 14.307

10.  Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes.

Authors:  K Whaley
Journal:  J Exp Med       Date:  1980-03-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Complement System: a Neglected Pathway in Immunotherapy.

Authors:  Anne Bordron; Cristina Bagacean; Adrian Tempescul; Christian Berthou; Eléonore Bettacchioli; Sophie Hillion; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

2.  Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I.

Authors:  Jitendra Kumar; Viveka Nand Yadav; Swastik Phulera; Ashish Kamble; Avneesh Kumar Gautam; Hemendra Singh Panwar; Arvind Sahu
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

3.  Genotype-phenotype correlations of low-frequency variants in the complement system in renal disease and age-related macular degeneration.

Authors:  M J Geerlings; E B Volokhina; E K de Jong; N van de Kar; M Pauper; C B Hoyng; L P van den Heuvel; A I den Hollander
Journal:  Clin Genet       Date:  2018-07-10       Impact factor: 4.438

4.  Effect of rare coding variants in the CFI gene on Factor I expression levels.

Authors:  Sarah de Jong; Elena B Volokhina; Anita de Breuk; Sara C Nilsson; Eiko K de Jong; Nicole C A J van der Kar; Bjorn Bakker; Carel B Hoyng; Lambert P van den Heuvel; Anna M Blom; Anneke I den Hollander
Journal:  Hum Mol Genet       Date:  2020-08-11       Impact factor: 6.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.